Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000179680 | SCV000231968 | uncertain significance | not provided | 2016-07-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000624879 | SCV000742727 | uncertain significance | Inborn genetic diseases | 2017-10-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763668 | SCV000894548 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12; Usher syndrome type 1D; Pituitary adenoma 5, multiple types | 2021-12-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001331235 | SCV001523229 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12 | 2019-05-03 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002509282 | SCV002819409 | uncertain significance | not specified | 2023-07-25 | criteria provided, single submitter | clinical testing | Variant summary: CDH23 c.9524G>A (p.Arg3175His) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00028 in 246978 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in CDH23 causing Usher Syndrome (0.00028 vs 0.0032), allowing no conclusion about variant significance. c.9524G>A has been reported in the literature in individuals affected with Usher Syndrome or non-syndromic hearing loss (e.g. Astuto_2002, Usami_2008, Cabanillas_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Usher Syndrome. At least two publications report experimental evidence evaluating an impact on protein function (e.g. Yonezawa_2006, Takahashi_2016), suggesting that the variant does not alter protein localization but may impact microtubule formation. However, these findings do not allow convincing conclusions about the variant effect. The following publications have been ascertained in the context of this evaluation (PMID: 12075507, 29986705, 27349180, 18368581, 16281288). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=5) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Invitae | RCV000179680 | SCV003263719 | likely benign | not provided | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003474936 | SCV004212366 | uncertain significance | Pituitary adenoma 5, multiple types | 2022-08-02 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276932 | SCV001463589 | uncertain significance | Usher syndrome type 1 | 2020-09-16 | no assertion criteria provided | clinical testing |